Literature DB >> 23807119

Influence of human myasthenia gravis thymus on the differentiation of human cord blood stem cells in SCID mice.

Qian Ru Li1, Ping Ping Liu, Xiao Yan Xuan, Sha Sha Guan, Ying Du, Feng Gao, Qing Yong Zhang.   

Abstract

The normal thymus contributes to T lymphocytes differentiation and induction of tolerance to self-antigens. Myasthenia gravis (MG) is characterized by abnormal thymic hyperplasia. To assess the potential influence of MG-thymus on the differentiation of T lymphocytes differentiation, we used the MG-thymus transplanted severe combined immunodeficiency (SCID) mice model to evaluate the human cord blood stem cells differentiation. Thymus fragments from MG patient and human cord blood stem cells were transplanted into SCID mice successively. SCID mice were observed to develop sustained human T lymphocytes and a functional anti-tumor immune. The levels of various T cell subsets in SCID mice with MG-thymus were different from that of control group. Among that, the frequency of CD4(+)CD25(+) T cells was significant lower in SCID mice with MG-thymus. The deficiency of CD4(+)CD25(+) T cells seens to contribute to the pathogenesis of MG.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23807119     DOI: 10.1007/s10072-013-1476-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  16 in total

1.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

2.  Analysis of the human thymic perivascular space during aging.

Authors:  K G Flores; J Li; G D Sempowski; B F Haynes; L P Hale
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

3.  Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage.

Authors:  Julie Cabarrocas; Cécile Cassan; Fay Magnusson; Eliane Piaggio; Lennart Mars; Jens Derbinski; Bruno Kyewski; David-Alexandre Gross; Benoit L Salomon; Khashayarsha Khazaie; Abdelhadi Saoudi; Roland S Liblau
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-18       Impact factor: 11.205

4.  Antigen-specific T-cell activation in hyperplastic thymus in myasthenia gravis.

Authors:  Kimiaki Utsugisawa; Yuriko Nagane; Shigeaki Suzuki; Ryushi Kondoh
Journal:  Muscle Nerve       Date:  2007-07       Impact factor: 3.217

5.  The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.

Authors:  E Meinl; W E Klinkert; H Wekerle
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

6.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

Authors:  Anna Balandina; Sandrine Lécart; Philippe Dartevelle; Abdelhadi Saoudi; Sonia Berrih-Aknin
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

7.  Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice.

Authors:  T Lapidot; F Pflumio; M Doedens; B Murdoch; D E Williams; J E Dick
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

8.  The defect in murine severe combined immune deficiency: joining of signal sequences but not coding segments in V(D)J recombination.

Authors:  M R Lieber; J E Hesse; S Lewis; G C Bosma; N Rosenberg; K Mizuuchi; M J Bosma; M Gellert
Journal:  Cell       Date:  1988-10-07       Impact factor: 41.582

9.  Myogenesis in thymic transplants in the severe combined immunodeficient mouse model of myasthenia gravis. Differentiation of thymic myoid cells into striated muscle cells.

Authors:  S Spuler; A Marx; T Kirchner; R Hohlfeld; H Wekerle
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

10.  Suppressor T cells in human diseases.

Authors:  Clare Baecher-Allan; David A Hafler
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.